How long should you take Erdafitinib?

Erdafitinib, also known asBalversa, is an oral anticancer drug that is a multi-target tyrosine kinase inhibitor. It inhibits the tyrosine kinase on the surface of tumor cells to prevent the proliferation and spread of tumor cells, thereby achieving the effect of treating malignant tumors. In addition, erdafitinib can also inhibit the angiogenesis of tumor cells, cut off the nutrient supply to tumors, and further curb their growth.

In clinical practice, erdafitinib is mainly used to treat adult patients with locally advanced or metastatic urothelial carcinoma, especially those with susceptible FGFR3 or FGFR2 gene alterations. The starting dose is usually 8 mg taken orally once daily with or without food. If the patient's serum phosphorus levels fall below target for a certain period of time, the dose may be increased to 9 mg daily. Treatment continues until disease progression or toxicity that the patient cannot tolerate.

Regarding the duration of use of erdafitinib, it does not stop and reuse it according to a fixed cycle. Instead, its use is continued until the patient's condition changes or intolerable side effects occur. Therefore, there is no fixed“take and stop” rule.

However, it is worth noting that although erdafitinib can effectively control the growth and spread of tumors, it may also cause some adverse reactions, such as hyperphosphatemia, stomatitis, fatigue, diarrhea, etc. Therefore, during the use of erdafitinib, patients need to closely monitor their physical condition and receive regular evaluation and adjustment of treatment plans from their doctors.

In summary, erdafitinib is an important anti-cancer drug, and its use should be determined based on the patient's specific situation and physician guidance, rather than following a fixed discontinuation and resumption cycle.